Ken Fisher’s Harmony Biosciences HRMY Stock Holding History

Ken Fisher’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-116	Closed	-$3.8K	–	1045
2023 Q3	$3.8K	Hold	116	–	–	﹤0.01%	1123
2023 Q2	$4.08K	Buy	+116	New	+$4K	﹤0.01%	1123

Other funds holding HRMY

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Ken Fisher's HRMY Position: Q4 2023 in Review

Ken Fisher sold out of Harmony Biosciences (HRMY) in Q4 2023, closing a stake of 116 shares — an estimated $3.8K sold.

Ken Fisher first reported a position in HRMY in Q2 2023 and held it in 2 quarters. The position peaked at $4.08K in Q2 2023. 221 funds tracked by Wall St. Rank hold HRMY as of Q4 2023.

Ken Fisher reported no remaining Harmony Biosciences position as of Q4 2023 after selling out during the quarter.
Ken Fisher sold 116 Harmony Biosciences shares in Q4 2023, an estimated $3.8K.
Ken Fisher first reported a position in Harmony Biosciences in Q2 2023 and held it in 2 quarters.
Ken Fisher's Harmony Biosciences position peaked at $4.08K in Q2 2023.
221 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2023.

Based on Fisher Asset Management's 13F filing for Q4 2023, filed 6 Feb 2024.